Wells Fargo lowered the firm’s price target on Beam Therapeutics to $105 from $125 and keeps an Overweight rating on the shares. The firm notes steady progress in the SCD clinical program, and looks forward to updates on the ESCAPE program that can expand the SCD market considerably according to KOL feedback, as well as updates in the in vivo LNP programs for AATD and GSDIa.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
- Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics reports Q4 EPS (54c), consensus ($1.33)
- Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
